20 May, EOD - Indian

SENSEX 81186.44 (-1.06)

Nifty 50 24683.9 (-1.05)

Nifty Bank 54877.35 (-0.98)

Nifty IT 37283.5 (-0.52)

Nifty Midcap 100 56182.65 (-1.62)

Nifty Next 50 66165.5 (-1.84)

Nifty Pharma 21456.15 (-1.31)

Nifty Smallcap 100 17483 (-0.94)

20 May, EOD - Global

NIKKEI 225 37529.49 (0.08)

HANG SENG 23681.48 (1.49)

S&P 5963.83 (-0.35)


Hot Pursuit News

You are Here : Home > News > Hot Pursuit News >

(12 Aug 2024, 12:44)

Morepen Labs soars after stellar Q1 performance

Morepen Laboratories jumped 4.70% to Rs 60.86 after the company reported a consolidated net profit of Rs 36.17 crore in Q1 FY25, which is a rise of 147% as compared with the PAT of Rs 14.63 crore in Q1 FY24.


Net revenue increased by 14% year-over-year (YoY) to Rs 458.64 crore during the period under review.

The company holds a strong position in the Blood Glucometers and Blood Pressure (BP) Monitors markets. In Q1 FY25, the medical devices business recorded revenue of Rs 138 crore, marking a 20% growth year-on-year.

Pharma segment Q1 FY25 revenue at Rs 320 crore registered a growth of 11% year-on-year, and it represents 70% of consolidated Q1 FY25 quarterly revenues.

EBIDTA improved by 93% to Rs 55.05 crore in Q1 FY25 from Rs 28.51 crore in Q1 FY24.

Profit before tax in Q1 FY25 stood at Rs 48.17 crore, up by 135% from Rs 20.51 crore in Q1 FY24.

Morepen Laboratories said that the company’s Blood Glucometer meter capacity would be doubled to 5.0 million meter pa from the current 2.5 million meter, while strip manufacturing capacity will increase from 500 million strips to 700 million strips per annum within the next 18 months.

The company has successfully completed the subscription of a QIP for Rs. 200 crores on 5 August 2024. The issue was oversubscribed by 1.68 times, demonstrating strong confidence from institutional investors.

Marquee global investors like Bank of America Securities Europe (BOFA), Samsung India, Citigroup, Societe Generale, Nomura, BNP Paribas, Morgan Stanley and Eminence are some of the select names that have partnered with Morepen, paving the way for a promising future.

Sushil Suri, chairman and managing director of Morepen Laboratories, commented on the QIP, stating, “This strategic fundraise marks a pivotal point in the company’s growth journey. With the influx of this new capital, we will accelerate our capacity expansion plans and broaden our market reach.”

Morepen Laboratories is an established player in domestic and international Active Pharmaceutical Ingredients ('API') markets. It is also planning to enter the anti-cancer segment by considering development of various potential candidates from list of top 100 synthetic molecules. The company also engaged in home diagnostics products, formulations and grooming products under the brand name GUBB.

More News

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +